New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:25 EDTAMGN, MMMAmgen appoints David Meline CFO
Amgen (AMGN) announced the appointment of David W. Meline as EVP and CFO, effective July 21. He will be responsible for Amgen's finance and investor relations operations, reporting to Robert A. Bradway, chairman and CEO. Meline will succeed Michael A. Kelly, who served as acting CFO since January 2014. Meline joins Amgen from 3M Company (MMM), where he most recently served SVP and CFO, responsible for all financial activities for 3M across 70 countries of operation.
News For AMGN;MMM From The Last 14 Days
Check below for free stories on AMGN;MMM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
21:02 EDTMMM3M completes acquisition of Sumitomo Electric Industries interest in Sumitomo 3M
3M announced that it has completed its acquisition, through Sumitomo 3M, of Sumitomo Electric Industriesí 25% interest in Sumitomo 3M for 90B Japanese Yen, approximately $865M at current exchange rates. 3M is now the sole owner and the business will be known as 3M Japan. Sumitomo 3M was established in 1961 as a joint venture between 3M, Sumitomo Electric Industries and NEC. In 2003, 3M acquired NECís 25% stake, which increased 3Mís interest to 75%. On a GAAP-reported basis, 3M estimates the acquisition will add approximately 8c per share to earnings during the first 12 months following closing.
12:50 EDTAMGNEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 28, 2014
09:18 EDTAMGNAmgen anounces Evolocumab YUKAWA-2 study meets co-primary endpoints
Subscribe for More Information
09:04 EDTAMGNAmgen submits evolocumab BLA to FDA
Subscribe for More Information
August 27, 2014
09:20 EDTAMGNFDA grants Amgen priority review designation for ivabradine
Amgen announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure. Ivabradine is an oral drug that inhibits the If current in the sinoatrial node, the body's cardiac pacemaker. The New Drug Application is based on global clinical trial data from the Phase 3 SHIFT, or Systolic Heart failure treatment with the If inhibitor ivabradine Trial), study. The SHIFT study compared ivabradine to placebo on top of standard-of-care therapies, including beta-blockers, in more than 6,500 patients in sinus rhythm with reduced left ventricular function and heart rate greater than 70 beats per minute.
August 26, 2014
11:21 EDTAMGNAmgen added to short term buy list at Deutsche Bank
Subscribe for More Information
09:22 EDTMMM3M reaches group purchasing agreement with Premier, Inc
3M Critical & Chronic Care Solutions announces that it has reached a group purchasing agreement with health care alliance company Premier, Inc. for multiple catheter securement and stability products. In a move aimed at bringing greater economic efficiencies to Premierís more than 100,000 health care provider members, the new agreement allows them to take advantage of special pricing and terms pre-negotiated by Premier. The purchasing contract covers products including Tegaderm CHG Chlorhexidine Gluconate I.V. Securement Dressings and Tegaderm I.V. Advanced Securement Dressings as well as the 3M PICC/ CVC Securement Device + Tegaderm I.V. Advanced Securement Dressing, a sutureless securement system.
August 25, 2014
16:17 EDTAMGNWestern Digital CFO Leyden to retire, Olivier Leonetti to succeed
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.
09:01 EDTMMM3M Company announces investment in Smart Energy Instruments
3M New Ventures Ė the corporate venture arm of 3M Ė announced an equity stake in Toronto-based Smart Energy Instruments, a move that will further accelerate SEIís efforts in developing electronic chipsets with high-precision, real-time monitoring capabilities for smart grids, as well as give 3M a bigger presence in the energy sector. The investment from 3M New Ventures comes as several existing stakeholders also bolstered their equity in SEI, including Venturelink Funds, ArcTern Ventures and the Ontario Capital Growth Corp. Together, the financing round, led by 3M New Ventures, totaled $5M. Other details of the transaction were not disclosed.
August 19, 2014
05:11 EDTAMGNGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
17:25 EDTAMGNAmgen announces AMG 416 study met its primary and all secondary endpoints
Amgen announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism, SHPT, in patients with chronic kidney disease,CKD, receiving hemodialysis, met its primary and all secondary endpoints. "The results from this second Phase 3 study help to confirm that AMG 416 could become an important new treatment option for dialysis patients with secondary hyperparathyroidism," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Despite the variety of options available for the treatment of this disease, an unmet need remains for an intravenous therapy that can be administered along with hemodialysis. We look forward to sharing results of a head-to-head study evaluating AMG 416 compared to cinacalcet next year."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use